

India's first MicroRNA based blood test for breast cancer screening

17 October 2025 | News

Cantel™ leverages proprietary miRNA signatures, validated through extensive clinical trials



PrecisionRNA Biotech (Prerna), a healthcare startup from Hyderabad, has announced the launch of Cantel™, India's first microRNA-based blood test for breast cancer screening.

This groundbreaking test is set to transform early detection by offering a simple, convenient, and highly accurate alternative to traditional methods, addressing the critical screening gap that has led to late-stage diagnosis of breast cancer in India.

In a country where less than 2% of women are screened for breast cancer, Cantel™ offers a scalable solution. Unlike mammography, which is often hindered by cost, accessibility issues, and social stigma, Cantel™ is a minimally invasive blood test that can be performed at home or at a local diagnostic center. No compression, no imaging, and no radiation. This convenience is designed to significantly increase screening adherence and improve survival rates, which are currently among the lowest globally.

The test utilises the power of microRNAs (miRNAs), small molecules that act as dynamic biomarkers for disease. The 2024 Nobel Prize in Medicine recognized the discovery of microRNAs and their role in gene regulation, highlighting their significance in modern diagnostics. Cantel™ leverages proprietary miRNA signatures, validated through extensive clinical trials, to detect early molecular signals of breast cancer with high sensitivity and specificity.

"For far too long, breast cancer detection in India has been reactive. With Cantel™, we're making it proactive, accessible, and designed around women's real lives, empowering them to take control of their health with confidence and ease," said Siddharth Reddy, Co-founder of CANTEL™ and a serial healthcare entrepreneur. "This is not just a diagnostic innovation. This is a step toward building a national health habit around early detection."